| |
Learn more about targeted marketing solutions from AmerisourceBergen.
|
|
|
Tuesday, November 29, 2022 | 2pm ET / 11am PT Process development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise in a field that is very dynamic and accelerating fast. Outsourcing gives you direct access to infrastructure, experience, and a team who has done this before and can quickly generate meaningful data taking the guesswork out of process development. Register now.
|
|
| By Andrea Park 2022 is undoubtedly a fraught time in the history of the women’s movement, but it is also an inspiring one, as people from every corner of the globe come together in support of the idea that women deserve equal rights. That double-edged sentiment echoes throughout this year’s list of the 20 fiercest women in life sciences. |
|
|
|
By Ben Adams Eli Lilly has become the first Big Pharma to fall victim to the uptick of fake Twitter handles that are cropping up under the new Twitter Blue paid accounts that Elon Musk recently pushed through. A user pretending to be the Indianapolis company tweeted out a message saying: “We are excited to announced insulin is free now.” |
By Andrea Park With only days to go until the former Theranos CEO is sentenced for fraud, attorneys for Holmes and for the U.S. government remain at loggerheads over a suitable punishment. |
By Nick Paul Taylor Deep into the fall season, biotechs are freeing themselves of dead wood at a rapid pace. The latest batch of quarterly updates saw Atreca, aTyr Pharma, Histogen, Lisata Therapeutics, Poseida Therapeutics and Rain Therapeutics trim their pipelines. |
|
Monday, December 5, 2022 | 11am ET / 8am PT The data behind the scenes must match and reflect the physical goods moving through the supply chain. In this webinar, we will discuss the four major components of compliance and how to get the data right to let the product flow. Register now.
|
|
By Angus Liu Novartis CEO Vas Narasimhan is still not done with his restructuring. The Swiss pharma is weighing various options, including sales, for its ophthalmology and respiratory disease businesses, Bloomberg reports. |
By Annalee Armstrong,James Waldron,Max Bayer Another failure of an amyloid medicine for Alzheimer’s disease has companies, analysts and patient advocacy groups circling the wagons to once again defend the theory and the future of research into the devastating neurological disorder. |
By Nick Paul Taylor Roche’s bet on the resurrection of Alzheimer’s disease candidate gantenerumab has flopped. The drug candidate failed to improve the rate of cognitive and functional decline in a pair of phase 3 clinical trials, delivering yet another blow to the field. |
By Helen Floersh In the world of precision oncology, it’s something like the Holy Grail: the ability to genetically fine-tune a cancer patient’s immune cells into weapons that target their specific tumor, without harming healthy tissue. Now, for the first time in humans, PACT Pharma has shown that it is indeed possible. |
By Fraiser Kansteiner In a phase 2/3 trial of more than 500 adults, Moderna’s bivalent booster mRNA 1273.222 triggered a “significantly higher” immune response against the BA.4 and BA.5 omicron subvariants compared to an auxiliary dose of the company’s standard vaccine, mRNA-1273, which bears the commercial moniker Spikevax. |
By Zoey Becker A protracted legal fight over an alleged "pay-for-delay" deal on AbbVie's Alzheimer's disease drug Namenda may be nearing its end as the sides have reached a preliminary settlement. |
By Kevin Dunleavy The rush is on as biopharma companies from the west are flocking to Asia and, more specifically, to business-friendly Singapore in their hopes of tapping into a massive and growing market. Monday, BioNTech revealed more about its plan to establish a stronghold on the island nation, saying it had acquired a manufacturing facility from Novartis that will also serve as its Asia-Pacific regional headquarters. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we share this week's headlines and discuss the 2022 honorees in our annual Fiercest Women in Life Sciences report. |
|
|---|
|
|
|
Wednesday, November 30, 2022 | 11am ET / 8am PT In this webinar, we will show how data centricity, digitalization and automation streamlines CMC content authoring and why it is the most viable solution to tackle the associated challenges. Register now.
|
|
| PodcastHow can Medical Affairs divisions bring greater value to their organizations and practitioners every day? Sponsored by: Medscape Medical Affairs |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| eBookSee how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more. Sponsored by: Health Catalyst |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
